{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:23:32Z","timestamp":1790720612025,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The German annual drug prescription-report has indicated overuse of proton pump inhibitors (PPIs) for many years; however, little was known about the characteristics of people using PPIs. This study aimed to provide comprehensive utilization data and describe frequencies of potential on- and off-label PPI-indications in Bavaria, Germany.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Claims data of statutorily insured people from 2010 to 2018 were used. Defined daily doses (DDDs) of PPIs by type of drug, prevalence of PPI-use and DDDs prescribed per 1000 insured people\/day were analyzed. For 2018, proportions of users and DDDs per 1000 insured people were calculated by age and sex. To elucidate changes in prescribing practices due to a suspected drug-drug interaction, we examined co-prescribing of clopidogrel and PPIs between 2010 and 2018. For PPI new users, sums of DDDs and frequencies of potential indications were examined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>PPI prescribing increased linearly from 2010 to 2016 and gradually decreased from 2016 to 2018. In 2018, 14.7% of women and 12.2% of men received at least one prescription, and 64.8 DDDs (WHO-def.) per 1000 insured people\/day were prescribed. Overall, omeprazole use decreased over the observation period and was steadily replaced by pantoprazole, especially when co-prescibed with clopidogrel. An on-label PPI-indication was not reported at first intake in 52.0% of new users.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The utilization of prescribed PPIs has decreased since 2016. However, a large proportion of new PPI-users had no documentation of a potential indication, and the sums of DDDs prescribed often seemed not to comply with guidelines.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-021-03257-z","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T01:02:28Z","timestamp":1638925348000},"page":"657-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010\u20132018"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-283X","authenticated-orcid":false,"given":"Ina-Maria","family":"R\u00fcckert-Eheberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nolde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayeon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"G\u00fcntner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"G\u00fcnter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Meisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Linseisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Amann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian-Edgar","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"3257_CR1","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1055\/s-0034-1385202","volume":"52","author":"H Koop","year":"2014","unstructured":"Koop H, Fuchs KH, Labenz J et al (2014) S2k-Leitlinie: Gastro\u00f6sophageale Refluxkrankkheit unter Federf\u00fchrung der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS):AWMF Register Nr. 021\u2013013 (S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021\u2013013). Z Gastroenterol 52:1299\u20131346. https:\/\/doi.org\/10.1055\/s-0034-1385202","journal-title":"Z Gastroenterol"},{"key":"3257_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1055\/s-0042-102967","volume":"54","author":"W Fischbach","year":"2016","unstructured":"Fischbach W, Malfertheiner P, Lynen Jansen P et al (2016) S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit (S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease). Z Gastroenterol 54:327\u2013363. https:\/\/doi.org\/10.1055\/s-0042-102967","journal-title":"Z Gastroenterol"},{"key":"3257_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrgastro.2017.117","volume":"14","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Kandulski A, Venerito M (2017) Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol 14:697\u2013710. https:\/\/doi.org\/10.1038\/nrgastro.2017.117","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3257_CR4","doi-asserted-by":"publisher","first-page":"175628481877794","DOI":"10.1177\/1756284818777943","volume":"11","author":"\u00d3\u00d6 H\u00e1lfd\u00e1narson","year":"2018","unstructured":"H\u00e1lfd\u00e1narson \u00d3\u00d6, Potteg\u00e5rd A, Bj\u00f6rnsson ES et al (2018) Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol 11:1756284818777943. https:\/\/doi.org\/10.1177\/1756284818777943","journal-title":"Therap Adv Gastroenterol"},{"key":"3257_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00228-019-02810-1","volume":"76","author":"M Lassalle","year":"2020","unstructured":"Lassalle M, Le Tri T, Bardou M et al (2020) Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 76:449\u2013457. https:\/\/doi.org\/10.1007\/s00228-019-02810-1","journal-title":"Eur J Clin Pharmacol"},{"key":"3257_CR6","doi-asserted-by":"publisher","first-page":"175628482091374","DOI":"10.1177\/1756284820913743","volume":"13","author":"B Daniels","year":"2020","unstructured":"Daniels B, Pearson S-A, Buckley NA et al (2020) Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013\u20132016. Therap Adv Gastroenterol 13:1756284820913743. https:\/\/doi.org\/10.1177\/1756284820913743","journal-title":"Therap Adv Gastroenterol"},{"key":"3257_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.12613","volume":"43","author":"M Naunton","year":"2018","unstructured":"Naunton M, Peterson GM, Deeks LS et al (2018) We have had a gutful: the need for deprescribing proton pump inhibitors. J Clin Pharm Ther 43:65\u201372. https:\/\/doi.org\/10.1111\/jcpt.12613","journal-title":"J Clin Pharm Ther"},{"key":"3257_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.552102","volume":"11","author":"M Matuz","year":"2020","unstructured":"Matuz M, Benk\u0151 R, Engi Z et al (2020) Use of proton pump inhibitors in Hungary: mixed-method study to reveal scale and characteristics. Front Pharmacol 11:552102. https:\/\/doi.org\/10.3389\/fphar.2020.552102","journal-title":"Front Pharmacol"},{"key":"3257_CR9","volume-title":"Arzneiverordnungs-Report 2019","author":"U Schwabe","year":"2020","unstructured":"Schwabe U, Paffrath D, Ludwig W-D et al (2020) Arzneiverordnungs-Report 2019. Springer-Verlag GmbH Deutschland, Berlin"},{"key":"3257_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1055\/s-0034-1384973","volume":"53","author":"F Hoffmann","year":"2015","unstructured":"Hoffmann F, Glaeske G, Schmiemann G (2015) Steigende Verordnungszahlen von Protonenpumpenhemmern im ambulant-\u00e4rztlichen Bereich \u00fcber die Jahre 2005\u20132013 (Increased prescribing of proton pump inhibitors in ambulatory care over the years 2005\u20132013). Z Gastroenterol 53:95\u2013100. https:\/\/doi.org\/10.1055\/s-0034-1384973","journal-title":"Z Gastroenterol"},{"key":"3257_CR11","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1345\/aph.1M051","volume":"43","author":"NB Norgard","year":"2009","unstructured":"Norgard NB, Mathews KD, Wall GC (2009) Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 43:1266\u20131274. https:\/\/doi.org\/10.1345\/aph.1M051","journal-title":"Ann Pharmacother"},{"key":"3257_CR12","unstructured":"European Medicines Agency (2010) Interaction between clopidogrel and proton-pump inhibitors: CHMP updates warning for clopidogrel-containing medicines. https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-interaction-between-clopidogrel-proton-pump-inhibitors_en.pdf. Accessed 09 Jul 2021"},{"key":"3257_CR13","unstructured":"Bl\u00fcmel M, Spranger A, Achstetter K et al (2020) Germany: Health system review. Health Systems in Transition. WHO - European Obeservatory on Health Systems and Policies, TU Berlin, Copenhagen"},{"key":"3257_CR14","unstructured":"Chaibi S, Schulze Ehring F, Verband der Privaten Krankenversicherung e.V. (2019) PKV-Regionalatlas Bayern: Regionale Bedeutung der Privatversicherten f\u00fcr die medizinische Versorgung unter besonderer Ber\u00fccksichtigung des l\u00e4ndlichen Raums"},{"key":"3257_CR15","unstructured":"Ochmann R, Albrecht M, Schiffhorst G et al (2020) Geteilter Krankenversicherungsmarkt: Risikoselektion und regionale Verteilung der \u00c4rzte, Bertelsmann Stiftung, G\u00fctersloh"},{"key":"3257_CR16","unstructured":"The Bavarian Association of Statutory Health Insurance Physicians About Us. https:\/\/www.kvb.de\/fileadmin\/kvb\/dokumente\/UeberUns\/KVB-About-us.pdf. Accessed 13 Jul 2021"},{"key":"3257_CR17","unstructured":"Wissenschaftliches Institut der AOK (2018) Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen: Amtliche Fassung des ATC-Index mit DDD-Angaben f\u00fcr Deutschland im Jahre 2018. https:\/\/www.dimdi.de\/dynamic\/de\/arzneimittel\/atc-klassifikation\/, Berlin"},{"key":"3257_CR18","unstructured":"World Health Organization (WHO) Collaborating center for drug statistics methodology ATC \/ DDD index, https:\/\/www.whocc.no\/atc_ddd_index\/, Accessed March 2021"},{"key":"3257_CR19","unstructured":"Fricke U, Zawinell A, Wissenschaftliches Insitut der AOK (2005) GKV-Arzneimittelindex: Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen f\u00fcr den deutschen Arzneimittelmarkt gem\u00e4\u00df \u00a7 73 Abs. 8 Satz 5 SGB V. Beschlussfasssung der Arbeitsgruppe ATC\/DDD des Kuratoriums f\u00fcr Fragen der Klassifikation im Gesundheitswesen am 2. Dezember 2005.\u00a0Bonn"},{"key":"3257_CR20","unstructured":"German Federal Ministry of Health KM-6 - Member statistics: https:\/\/www.bundesgesundheitsministerium.de\/themen\/krankenversicherung\/zahlen-und-fakten-zur-krankenversicherung\/mitglieder-und-versicherte.html), Accessed November 2020"},{"key":"3257_CR21","unstructured":"https:\/\/www.medicines.org.uk\/emc Accessed March 2021"},{"key":"3257_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00108-019-0610-y","volume":"60","author":"W Fischbach","year":"2019","unstructured":"Fischbach W (2019) Medikamenteninduzierte gastrointestinale Blutung (Drug-induced gastrointestinal bleeding). Internist (Berl) 60:597\u2013607. https:\/\/doi.org\/10.1007\/s00108-019-0610-y","journal-title":"Internist (Berl)"},{"key":"3257_CR23","unstructured":"Kassen\u00e4rztliche Vereinigung Bayerns https:\/\/www.kvb.de\/verordnungen\/arzneimittel\/wirkstoffvereinbarung\/: Accessed February 2021"},{"key":"3257_CR24","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s11894-000-0013-0","volume":"2","author":"AB Thomson","year":"2000","unstructured":"Thomson AB (2000) Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2:482\u2013493. https:\/\/doi.org\/10.1007\/s11894-000-0013-0","journal-title":"Curr Gastroenterol Rep"},{"key":"3257_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041529","volume":"10","author":"D Abrahami","year":"2020","unstructured":"Abrahami D, McDonald EG, Schnitzer M et al (2020) Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study. BMJ Open 10:e041529. https:\/\/doi.org\/10.1136\/bmjopen-2020-041529","journal-title":"BMJ Open"},{"key":"3257_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1177\/1756283X16650156","volume":"9","author":"A Potteg\u00e5rd","year":"2016","unstructured":"Potteg\u00e5rd A, Broe A, Hallas J et al (2016) Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Therap Adv Gastroenterol 9:671\u2013678. https:\/\/doi.org\/10.1177\/1756283X16650156","journal-title":"Therap Adv Gastroenterol"},{"key":"3257_CR27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00228-019-02798-8","volume":"76","author":"S-Y Yu","year":"2020","unstructured":"Yu S-Y, Lee B, McGuire TM et al (2020) Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison. Eur J Clin Pharmacol 76:547\u2013555. https:\/\/doi.org\/10.1007\/s00228-019-02798-8","journal-title":"Eur J Clin Pharmacol"},{"key":"3257_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1590\/1516-3180.2018.0019220318","volume":"136","author":"M Forgerini","year":"2018","unstructured":"Forgerini M, Mieli S, Mastroianni PdC (2018) Safety assessment of omeprazole use: a review. Sao Paulo Med J 136:557\u2013570. https:\/\/doi.org\/10.1590\/1516-3180.2018.0019220318","journal-title":"Sao Paulo Med J"},{"key":"3257_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00228-018-2564-8","volume":"75","author":"N Farhat","year":"2019","unstructured":"Farhat N, Haddad N, Crispo J et al (2019) Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000\u20132016. Eur J Clin Pharmacol 75:227\u2013235. https:\/\/doi.org\/10.1007\/s00228-018-2564-8","journal-title":"Eur J Clin Pharmacol"},{"key":"3257_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1055\/s-0043-116856","volume":"55","author":"M G\u00f6tz","year":"2017","unstructured":"G\u00f6tz M, Anders M, Biecker E et al (2017) S2k-Leitlinie Gastrointestinale Blutung (S2k Guideline Gastrointestinal Bleeding - Guideline of the German Society of Gastroenterology DGVS). Z Gastroenterol 55:883\u2013936. https:\/\/doi.org\/10.1055\/s-0043-116856","journal-title":"Z Gastroenterol"},{"key":"3257_CR31","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/ajg.2009.115","volume":"104","author":"FL Lanza","year":"2009","unstructured":"Lanza FL, Chan FKL, Quigley EMM (2009) Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104:728\u2013738. https:\/\/doi.org\/10.1038\/ajg.2009.115","journal-title":"Am J Gastroenterol"},{"key":"3257_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/apt.13649","volume":"44","author":"PF Haastrup","year":"2016","unstructured":"Haastrup PF, Paulsen MS, Christensen RD et al (2016) Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. Aliment Pharmacol Ther 44:78\u201387. https:\/\/doi.org\/10.1111\/apt.13649","journal-title":"Aliment Pharmacol Ther"},{"key":"3257_CR33","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/pds.1969","volume":"19","author":"S Hollingworth","year":"2010","unstructured":"Hollingworth S, Duncan EL, Martin JH (2010) Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf 19:1019\u20131024. https:\/\/doi.org\/10.1002\/pds.1969","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3257_CR34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000498967","volume":"101","author":"Y Sakata","year":"2020","unstructured":"Sakata Y, Tsuruoka N, Takedomi H et al (2020) A study on the status of proton pump inhibitor prescriptions using diagnosis procedure combination data in Japan. Digestion 101:308\u2013315. https:\/\/doi.org\/10.1159\/000498967","journal-title":"Digestion"},{"key":"3257_CR35","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/pds.3442","volume":"22","author":"SE Tett","year":"2013","unstructured":"Tett SE, Sketris I, Cooke C et al (2013) Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada. Pharmacoepidemiol Drug Saf 22:735\u2013743. https:\/\/doi.org\/10.1002\/pds.3442","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3257_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2036.2006.02727.x","volume":"23","author":"M Nocon","year":"2006","unstructured":"Nocon M, Labenz J, Willich SN (2006) Lifestyle factors and symptoms of gastro-oesophageal reflux \u2013 a population-based study. Aliment Pharmacol Ther 23:169\u2013174. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02727.x","journal-title":"Aliment Pharmacol Ther"},{"key":"3257_CR37","first-page":"591","volume":"62","author":"PC Konturek","year":"2011","unstructured":"Konturek PC, Brzozowski T, Konturek SJ (2011) Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol 62:591\u2013599","journal-title":"J Physiol Pharmacol"},{"key":"3257_CR38","doi-asserted-by":"publisher","unstructured":"Helgadottir H, Bjornsson ES (2019) Problems associated with deprescribing of proton pump inhibitors Int J Mol Sci 20 https:\/\/doi.org\/10.3390\/ijms20215469","DOI":"10.3390\/ijms20215469"},{"key":"3257_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/175436","volume":"2015","author":"JE Zwisler","year":"2015","unstructured":"Zwisler JE, Jarb\u00f8l DE, Lassen AT et al (2015) Placebo-controlled discontinuation of long-term acid-suppressant therapy: a randomised trial in general practice. Int J Family Med 2015:175436. https:\/\/doi.org\/10.1155\/2015\/175436","journal-title":"Int J Family Med"},{"key":"3257_CR40","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/MCG.0000000000000542","volume":"51","author":"H Helgad\u00f3ttir","year":"2017","unstructured":"Helgad\u00f3ttir H, Metz DC, Lund SH et al (2017) Study of gender differences in proton pump inhibitor dose requirements for GERD: a double-blind randomized trial. J Clin Gastroenterol 51:486\u2013493. https:\/\/doi.org\/10.1097\/MCG.0000000000000542","journal-title":"J Clin Gastroenterol"},{"key":"3257_CR41","first-page":"354","volume":"63","author":"B Farrell","year":"2017","unstructured":"Farrell B, Pottie K, Thompson W et al (2017) Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. Can Fam Physician 63:354\u2013364","journal-title":"Can Fam Physician"},{"key":"3257_CR42","doi-asserted-by":"publisher","first-page":"436","DOI":"10.5694\/mja18.00674","volume":"209","author":"P Bytzer","year":"2018","unstructured":"Bytzer P (2018) Deprescribing proton pump inhibitors: why, when and how. Med J Aust 209:436\u2013438. https:\/\/doi.org\/10.5694\/mja18.00674","journal-title":"Med J Aust"},{"key":"3257_CR43","unstructured":"Arriba https:\/\/arriba-hausarzt.de\/module\/ppi-protonenpumpen-hemmer-absetzen: accessed Decembre 2020"},{"key":"3257_CR44","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1186\/s13063-019-3728-2","volume":"20","author":"A Rieckert","year":"2019","unstructured":"Rieckert A, Becker A, Donner-Banzhof N et al (2019) Reduction of the long-term use of proton pump inhibitors by a patient-oriented electronic decision support tool (arriba-PPI): study protocol for a randomized controlled trial. Trials 20:636. https:\/\/doi.org\/10.1186\/s13063-019-3728-2","journal-title":"Trials"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03257-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03257-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03257-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T08:03:10Z","timestamp":1647417790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03257-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3257"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03257-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,8]]},"assertion":[{"value":"1 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics committee at the Ludwig Maximilians-University of Munich confirmed that an ethics approval was not needed since only anonymized claims data were used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Since only anonymized claims data were used, informed consent by the insured individuals was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}